Since activin or activin receptor antagonists are in clinical trials for other disorders, this finding opens the exciting perspective of using such inhibitors for the inhibition of skin cancer development, for example, in patients with skin cancer precursor lesions. This evidence concerns the gene INHBE and skin cancer.